Dapagliflozin

CAS Number: 461432-26-8

Molecular Formula: C21H25ClO6

Purity: Dapagliflozin 98% purity

About Dapagliflozin

Dapagliflozin (CAS 461432-26-8) represents a cornerstone in the modern API intermediates market, serving as a potent SGLT2 inhibitor essential for the treatment of type 2 diabetes and chronic kidney disease. Farxiga functions as a high-demand molecule within custom synthesis services, where the integration of high puri...

Synonyms

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
BMS 512148
BMS-512148
BMS512148

View all

Dapagliflozin Specifications

CAS Number

461432-26-8

Molecular Formula

C21H25ClO6

Molecular Weight

408.87 g/mol

IUPAC Name

(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

PubChem CID

9887712

HSN No

30049099

CAS Number

461432-26-8

Molecular Formula

C21H25ClO6

Molecular Weight

408.87 g/mol

IUPAC Name

(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

PubChem CID

9887712

HSN No

30049099

Molecular Weight

408.87 g/mol

Purity

Dapagliflozin 98% purity

Antidiabetic Agent

A selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults and children 10 years and older with type 2 diabetes mellitus

Cardiovascular Therapeutic

A prescription medication indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure or type 2 diabetes

Chronic Kidney Disease Treatment

A therapeutic agent utilized to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in patients with chronic kidney disease

SGLT2 Inhibitor

A potent and selective renal sodium-dependent glucose cotransporter 2 inhibitor used in biochemical research and pharmaceutical development to study glucose reabsorption and urinary glucose excretion.

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
BMS 512148
BMS-512148
BMS512148